Sanofi-Backed Voyager Therapeutics Hails Gene Therapy's Arrival
Executive Summary
Emerging Company Profile: With a pipeline of products for neurological diseases and a collaboration with Sanofi's Genzyme, Voyager Therapeutics is confident that its 'one-shot' gene therapy could be the answer to treating serious diseases of the brain. CEO Steven Paul shares development and funding plans and hopes to make Voyager's gene therapies the answer to neurological maladies.
You may also be interested in...
AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies
Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
Voyager's Parkinson's Gene Therapy Poised For Pivotal Trial Exploration
The Cambridge, Mass.-based biotech announced updated data from a Phase Ib trial of a gene therapy for Parkinson's disease, showing improvements in motor function and less time with dyskinesia.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.